ChemoCentryx Stock Loses More Than Half Its Value; Is This The Final Nail For Its Drug?

A panel of experts was split Thursday on whether to recommend approval for ChemoCentryx’s autoimmune disease drug — and CCXI stock plummeted to its lowest point in two years on Friday.
Read More